Shield Therapeutics PLC reported strong financial results for 2025, with net revenues and other income reaching $49.7 million, driven by a 56% growth in ACCRUFeR® net revenues to $45.8 million. The company achieved positive cash flow in Q4 2025 and expects to deliver an operating profit in 2026. Key highlights include
ACCRUFeR® becoming the #1 branded prescription oral iron in the US, with ~199,000 prescriptions dispensed and a 21% increase in average net selling price.
Expansion of global patient access through regulatory approvals and partnerships in Canada, South Korea, China, and Japan.
Reduced loss for the year to $17.7 million, compared to $27.2 million in 2024, due to revenue growth and disciplined expense management.
Strengthened balance sheet with cash and cash equivalents of $11.6 million as of December 31, 2025, and amended debt terms providing increased financial flexibility.
Anticipated strong growth in 2026, driven by continued ACCRUFeR® sales momentum, international expansion, and disciplined financial management.
| Financial Metric | 2024 | 2025 | Change |
|---|---|---|---|
| Group Net Revenues and Other Income ($M) | 32.0 | 49.7 | +55.3% |
| ACCRUFeR® Net Revenues ($M) | 29.3 | 45.8 | +56.3% |
| Loss for the Year ($M) | -27.2 | -17.7 | +34.9% |
| Cash and Cash Equivalents ($M) | 6.5 | 11.6 | +78.5% |
| Senior Secured Debt Drawn ($M) | N/A | 22.0 | N/A |
| U.S. ACCRUFeR® Prescriptions (thousands) | 150 | 199 | +32.7% |
| Average Net Selling Price ($) | 202 | 223 | +10.4% |
| ACCRUFeR® Prescribers (thousands) | N/A | 15 | N/A |
| Research and Development Expenditure ($M) | 4.3 | 1.8 | -58.1% |
| Financial Expense ($M) | 3.9 | 7.4 | +89.7% |
| Net Cash Inflow ($M) | -7.5 | 5.0 | N/A |